Icon
+91 94997 68112
Login Register

Kalydeco - (150 mg; Tablet, Oral)

Ivacaftor Vertex pharma
150 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
KALYDECO is indicated for the treatment CF in pediatric patients age 2-17 years of age who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation
Yes
** ***** **** ** ********* **** ***** ********* ******* ***** ** $***.**. *** ****** ** ***. *** ****** ***** * **** ** ** ****** '*** *** *** *********. ** ****** **** **** *** ****** ****** ** *** ****. ********* ** ****** ****** *** ******, ******** ****** ** ******** ****** ** ******. **, **** ** *** ******* *** ****** ******* ****** ******. ***** ** **** **, **** ****** **** ***** ** ****** ** '***.
Kalydeco Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9
*** ****** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* ******* *******
***** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* ******* *******
********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** *** \ ********* *** **, **** ******* **** ******* *** **** (******** ******) *** *** ****
***** **\ ** *** **, **** ******* ********* ******** ******* *** **** (******** ******) *** *** ****
********* ** \ ** *** **, **** ******* ********* ******** ******* *** **** (******** ******) *** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : *** ****** ******** ****** ****** ***** **'* **** ** ************* ** ****** '***.
  3. *** **, **** : ****** ****** ***** * **** ******* *** ****** ** ****** '***.
  4. *** *, **** : ***** ******** ****** ** ***** ****-** ******.
  5. *** **, **** : ****** ****** ***** * **** ******* ***** ** ****** '***.
  6. *** **, **** : ********* ******** ****** ** ***** ****-** ******.
  7. *** *, **** : ****** **** ********* **** ************ ** ****** '***.
  8. *** **, **** : ****** ****** **** ***** *** ********* **** ***** ****** ****** '***.
  9. *** **, **** : ****** ****** **** *** ****** **** ***** ****** ****** '***.
  10. : ****** ****** *** ***** ******* ********** **** ******* *****.
  11. *** **, **** : ****** ****** *** ***** ******* ********** **** ******* *****.
  12. *** *, **** : ****** ****** *** ********* ******* ********** **** ******* *****.
  13. *** *, **** : ****** *** *** ****** ******* ********** **** ************ ** ****** '*** *** '***.

Kalydeco - (25, 50, 75 mg/packet ; Oral Granules)

Ivacaftor Vertex pharma
25, 50, 75 mg/packet ; Oral Granules
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
None None
KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R and R117H.
Yes
********* ** ****** ****** *** ******, ******** ****** ** ******** ****** ** ******. **, **** ** *** ******* *** ****** ******* ****** ******.
Kalydeco Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
***** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** (***** ******)
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ ********* *** **, **** ******* **** ***** *** **** (******** ******)
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : ***** ******** ****** ***** *** ****-** ****** **** ******* '***, '***, *** '***
  3. *** **, **** : ****** **** ***** **** ************ ** ******* '***, '***, '***, *** '***.
  4. *** **, **** : ****** **** ***** **** ***** ****** ****** '***.
  5. *** **, **** : ***** ******** ****** ***** *** **** ** ****** **** ***** ****** ****** ** '***.
  6. *** **, **** : ****** **** ***** **** ************ ** ***** ****** ****** ** '***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.